Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more →
Incyte's $750M buyout rocked by pause on key trial, asset cull Read more →
Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more →
Talent to power Life Sciences
Tech talent for Life Sciences
« All Events
The agenda at BioInfect will focus on the issues surrounding the increasing threat of AMR and how it can be addressed.